Pharmacokinetics and Blood Pressure Response of Losartan in End-Stage Renal Disease

By Sica D.A.  

Clinical Pharmacokinetics, Vol. 38, Iss. 6, 2000-06 ,pp. : 519-526

Adis International

Access to resources Recommend Favorite

ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease

By Doggrell Sheila A  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 7, 2003-07 ,pp. : 1185-1188

Informa Healthcare

Access to resources Recommend Favorite

Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes

By Postma Maarten J   Kruidhof Hanneke   Berg Lolkje TW de Jong-van den   Zeeuw Dick de  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 9, 2003-09 ,pp. : 1543-1550

Informa Healthcare

Access to resources Recommend Favorite

The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy

By Carides George W.  

PharmacoEconomics, Vol. 24, Iss. 6, 2006-01 ,pp. : 549-558

Adis International

Access to resources Recommend Favorite

Losartan: double-barrel benefit in paediatric renal disorders

By  

Inpharma, Vol. 1, Iss. 1467, 2004-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite